Gilad Babchuk - Clearmind Medicine Head Communication
| CMND Stock | USD 1.30 0.02 1.56% |
Insider
Gilad Babchuk is Head Communication of Clearmind Medicine Common
| Address | 1220 West 6th Avenue, Vancouver, BC, Canada, V6H 1A5 |
| Phone | 604 260 1566 |
| Web | https://www.clearmindmedicine.com |
Clearmind Medicine Management Efficiency
The company has return on total asset (ROA) of (0.5795) % which means that it has lost $0.5795 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.679) %, meaning that it created substantial loss on money invested by shareholders. Clearmind Medicine's management efficiency ratios could be used to measure how well Clearmind Medicine manages its routine affairs as well as how well it operates its assets and liabilities. As of November 30, 2024, Return On Tangible Assets is expected to decline to -3.41. The current year's Return On Capital Employed is expected to grow to -13.37. At present, Clearmind Medicine's Total Current Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 224.1 K, whereas Other Current Assets are forecasted to decline to about 106.1 K.Similar Executives
| Showing other executives | INSIDER Age | ||
| Glenn Mattes | Tff Pharmaceuticals | 67 | |
| Anthony Hickey | Tff Pharmaceuticals | N/A | |
| MBA MD | Eliem Therapeutics | 63 | |
| Susan MS | Eliem Therapeutics | N/A | |
| , MBA | Molecular Partners AG | 51 | |
| Dale Christensen | Tff Pharmaceuticals | N/A | |
| James JD | Eliem Therapeutics | 58 | |
| Seth Lewis | Molecular Partners AG | N/A | |
| Michael Pitzner | Molecular Partners AG | N/A | |
| Jo PalmerPhillips | Eliem Therapeutics | N/A | |
| Andreas EMBA | Molecular Partners AG | 58 | |
| Erin Lavelle | Eliem Therapeutics | 47 | |
| Mark Lappe | Inhibrx | 57 | |
| Quinn Deveraux | Inhibrx | N/A | |
| Alexander Zurcher | Molecular Partners AG | 49 | |
| Harlan Weisman | Tff Pharmaceuticals | 72 | |
| Thomas Schwerzmann | Molecular Partners AG | N/A | |
| Patrick Amstutz | Molecular Partners AG | 49 | |
| Paul Manley | Tff Pharmaceuticals | N/A | |
| BS CPA | Inhibrx | 42 | |
| Christopher Cano | Tff Pharmaceuticals | 53 | |
Management Performance
| Return On Equity | -2.68 | ||||
| Return On Asset | -0.58 |
Clearmind Medicine Common Leadership Team
Elected by the shareholders, the Clearmind Medicine's board of directors comprises two types of representatives: Clearmind Medicine inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Clearmind. The board's role is to monitor Clearmind Medicine's management team and ensure that shareholders' interests are well served. Clearmind Medicine's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Clearmind Medicine's outside directors are responsible for providing unbiased perspectives on the board's policies.
| BCom BComm, CFO Director | ||
| Mylene Touboul, Accounting Manager | ||
| Gilad Babchuk, Head Communication | ||
| Adi Varon, Controller | ||
| Pr Haden, Vice Development | ||
| Pr MSW, Vice Development | ||
| Adi ZuloffShani, Chief Officer |
Clearmind Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Clearmind Medicine a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -2.68 | ||||
| Return On Asset | -0.58 | ||||
| Current Valuation | (2.41 M) | ||||
| Shares Outstanding | 4.07 M | ||||
| Shares Owned By Institutions | 17.31 % | ||||
| Number Of Shares Shorted | 187.57 K | ||||
| Price To Earning | (750.00) X | ||||
| Price To Book | 1.50 X | ||||
| EBITDA | (8.71 M) | ||||
| Net Income | (6.23 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Clearmind Medicine Common is a strong investment it is important to analyze Clearmind Medicine's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Clearmind Medicine's future performance. For an informed investment choice regarding Clearmind Stock, refer to the following important reports:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Clearmind Medicine Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Clearmind Medicine. If investors know Clearmind will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Clearmind Medicine listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.23) | Return On Assets (0.58) | Return On Equity (2.68) |
The market value of Clearmind Medicine Common is measured differently than its book value, which is the value of Clearmind that is recorded on the company's balance sheet. Investors also form their own opinion of Clearmind Medicine's value that differs from its market value or its book value, called intrinsic value, which is Clearmind Medicine's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Clearmind Medicine's market value can be influenced by many factors that don't directly affect Clearmind Medicine's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Clearmind Medicine's value and its price as these two are different measures arrived at by different means. Investors typically determine if Clearmind Medicine is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Clearmind Medicine's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.